We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
132 hedge funds and large institutions have $413M invested in ANI Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 50 increasing their positions, 30 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
73% more capital invested
Capital invested by funds: $239M → $413M (+$174M)
67% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 30
13% more funds holding
Funds holding: 117 → 132 (+15)
3.5% less ownership
Funds ownership: 57.11% → 53.6% (-3.5%)
36% less call options, than puts
Call options by funds: $2.3M | Put options by funds: $3.57M
Holders
132
Holders Change
+15
Holders Change %
+12.82%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
35
Increased
50
Reduced
30
Closed
19
Calls
$2.3M
Puts
$3.57M
Net Calls
-$1.27M
Net Calls Change
-$818K
Top Buyers
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$11.7M |
| 2 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$7.35M |
| 3 |
Morgan Stanley
New York
|
-$2.32M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$1.09M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.08M |
